Results 161 to 170 of about 9,288 (216)

Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis.

Journal of Cystic Fibrosis
BACKGROUND Highly effective modulators of the CFTR channel have been demonstrated to dramatically impact disease progression and outcome. However, real-world data indicates that the magnitude of the clinical benefit is not equal among all patients ...
G. Alicandro, A. Gramegna, F. Bellino, Sathya Calogero Sciarrabba, Chiara Lanfranchi, M. Contarini, M. Retucci, V. Daccò, Francesco Blasi   +8 more
semanticscholar   +1 more source

Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial.

The Lancet Respiratory Medicine
BACKGROUND CFTR modulators are approved for approximately 90% of people with cystic fibrosis in the USA and provide substantial clinical benefit. N1303K (Asn1303Lys), one of the most common class 2 CFTR defects, has not been approved for these therapies ...
G. M. Solomon, Rachel W. Linnemann, R. Rich, A. Streby, B. Buehler, Eric Hunter, Kadambari Vijaykumar, W. R. Hunt, J. Brewington, A. Rab, Shasha Bai, A. Westbrook, Carmel McNicholas-Bevensee, J. Hong, C. Manfredi, Cristina Barillà, S. Suzuki, B. R. Davis, E. J. Sorscher   +18 more
semanticscholar   +1 more source

Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor.

Journal of Cystic Fibrosis
BACKGROUND The constellation of hypertension, truncal obesity, impaired fasting glucose, low high-density lipoprotein, and hypertriglyceridemia is known as metabolic syndrome (MetSyn) and is associated with cardiovascular and other diseases.
Gregory A. Ratti, H. Smith, S. Mirfakhraee, J. Reisch, L. Cohen, R. Jain, James D. Finklea   +6 more
semanticscholar   +1 more source

Ivacaftor/ivacaftor/lumacaftor

Reactions Weekly, 2022
openaire   +1 more source

Elexacaftor/ivacaftor/tezacaftor/ivacaftor

Reactions Weekly, 2023
openaire   +1 more source

Elexacaftor/ivacaftor/tezacaftor/ivacaftor

Reactions Weekly, 2022
openaire   +1 more source

Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor

Digestive Diseases
Introduction: Cystic fibrosis transmembrane conductance regulator modulator therapy improves nutritional status and quality of life. Clinical trials have shown pancreatic insufficiency conversion, mostly in pediatric patients treated with ivacaftor ...
N. Stastna, L. Kunovský, Michal Svoboda, E. Pokojová, Lukáš Homola, M. Malá, Ž. Grácová, Barbora Jerabkova, Jana Skřičková, J. Trna   +9 more
semanticscholar   +1 more source

Ivacaftor/lumacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2023
openaire   +1 more source

Ivacaftor

Reactions Weekly, 2022
openaire   +2 more sources

Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO

Journal of Clinical Endocrinology and Metabolism
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective therapy that improves lung disease in people with cystic fibrosis (pwCF), but its effect on glucose tolerance and insulin secretion is unclear.
C. L. Chan, Meghan Shirley Bezerra, D. Stefanovski, R. Gallop, R. Walega, S. Donaldson, Carla A. Frederick, Steven D. Freedman, D. Gelfond, Lucas R. Hoffman, M. Narkewicz, Steven M. Rowe, S. Sagel, S. Schwarzenberg, G. Solomon, Michael S Stalvey, Andrea Kelly   +16 more
semanticscholar   +1 more source